hero image

Biogen Statement about Director Lynn Schenk

June 2, 2020 Company Statements

SchenkWe are thankful for the service of Lynn Schenk as a director of IDEC since 1995 and then a director of the merged Biogen company since 2004. Lynn will retire from the Biogen Board at the end of her current term, which expires at the 2020 annual meeting of stockholders.

As a director for more than two decades, Lynn has been part of the remarkable evolution of Biogen from one of the world’s first biotechnology companies to a neuroscience pioneer that today discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Throughout her tenure, Lynn, who was a National Association of Corporate Directors Top 100 Directors honoree in 2017, has been a vital contributor to the company and its Board. She chaired the board’s Nomination & Governance and Risk committees and served on the board’s compensation committee. Lynn’s experience in the public and private sector, as well as her strong public policy, government and legal experience, have been especially important to the company’s success in the highly regulated life sciences industry. She was and continues to be a mentor and champion of women in the company and in science.

Our Board of Directors is deeply grateful for her many contributions and long term of service to Biogen, and wishes her all the best in the future.

thumb
June 22, 2022
Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform

Biogen is collaborating with Happify Health to support people living with Multiple Sclerosis (MS) Happify Health’s platform supports the MS patient care journey, keeps patients abreast of treatment advances, helps support medication adherence, promotes holistic wellness goals, connects users with

thumb
June 21, 2022
European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate)

Patent covers approved dosing regimen for TECFIDERA and expires in 2028 CAMBRIDGE, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Patent Office has granted a patent that expires in February 2028 related to TECFIDERA ® (dimethyl fumarate).